Nevada
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
Black individuals in Nevada are least likely to be diagnosed early
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Nevada is not available over this period.
- In 2022, the most recent year of data available for this report, the COVID-19 pandemic continued to disrupt access to medical care, including delays and reductions in cancer diagnoses and screening. This led to a decline in incidence rates for most cancers, including lung cancer, and should not be interpreted as a reduction in the underlying cancer burden.
5-Year Survival Rate:
- Nationally, the five-year survival rate is 29.7%. Nevada is one of the 12 states for which survival data is not available as they do not track cases after diagnosis.
Early Diagnosis:
- In Nevada, 22.2% of cases are caught at an early stage, which is significantly lower than the national rate of 28.1%.
- Nevada ranks 49th among the 50 states with data on early-stage diagnosis, placing it in the bottom tier.
- Over the last five years, the early diagnosis rate in Nevada did not change significantly.
Lung Cancer Treatment
Biomarker Coverage:
- Nevada has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of August 2025.
Surgical Treatment:
- Nevada ranked 48th (out of 49 states with available data) with 14.2% of cases undergoing surgery as part of the first course of treatment, which is significantly lower than the national rate of 20.7%.
- This places Nevada in the bottom tier.
- Over the last five years, the percent of cases undergoing surgery in Nevada did not change significantly.
No Treatment:
- Nevada ranked 49th (out of 49 states with available data) with 36.9% of cases not receiving any treatment, which is significantly higher than the national rate of 21.0%.
- This places Nevada in the bottom tier.
- Over the last five years, the percent of cases receiving no treatment in Nevada did not change significantly.
Screening
Screening for High Risk:
- In Nevada, 14.0% of those at high risk were screened, which was not significantly different than the national rate of 18.2%.
- It ranks 42nd among all states, placing it in the below average tier.
- Screening rates in this year’s report have been updated to correct an error in the data source and should not be compared to previous reports.
Prevention
Tobacco Use:
- The 2023 smoking rate in Nevada is 14.2% and not significantly different than the national rate of 11.4%.
- It ranks 37th among all states, placing it in the below average tier.
Radon Exposure:
- In Nevada, 12.8% of radon test results were at or above the action level recommended by EPA.
- It ranks 12th among all states, placing it in the above average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 45.5 per 100,000 population among Black individuals in Nevada, significantly lower than the rate of 54.2 among Black individuals nationally, and not significantly different than the rate of 48.6 among white individuals in Nevada.
- Survival rates by race and ethnicity are not available for Nevada at this time. Nationally, the five-year survival rate among Black individuals is 27.1%, 9% lower than among white Americans.
- 18.7% of lung cancer cases are diagnosed at an early stage among Black individuals in Nevada, significantly lower than the rate of 25.1% among Black individuals nationally, and significantly lower than the rate of 23.1% among white individuals in Nevada.
- 12.2% of Black individuals with lung cancer in Nevada underwent surgery, significantly lower than the rate of 17.1% among Black individuals nationally, and significantly lower than the rate of 14.2% among white individuals in Nevada.
- 41.7% of Black individuals with lung cancer in Nevada did not receive any treatment, significantly higher than the rate of 22.7% among Black individuals nationally, and significantly higher than the rate of 36.5% among white individuals in Nevada.
Latino individuals:
- The rate of new lung cancer cases is 26.1 per 100,000 population among Latino individuals in Nevada, not significantly different than the rate of 27.9 among Latino individuals nationally, and significantly lower than the rate of 48.6 among white individuals in Nevada.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- 18.7% of lung cancer cases are diagnosed at an early stage among Latino individuals in Nevada, significantly lower than the rate of 23.9% among Latino individuals nationally, and significantly lower than the rate of 23.1% among white individuals in Nevada.
- 12.0% of Latino individuals with lung cancer in Nevada underwent surgery, significantly lower than the rate of 21.4% among Latino individuals nationally, and significantly lower than the rate of 14.2% among white individuals in Nevada.
- 37.4% of Latino individuals with lung cancer in Nevada did not receive any treatment, significantly higher than the rate of 25.8% among Latino individuals nationally, and not significantly different than the rate of 36.5% among white individuals in Nevada.
Asian or Pacific Islander individuals:
- The rate of new lung cancer cases is 32.2 per 100,000 population among Asian or Pacific Islanders individuals in Nevada, not significantly different than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 48.6 among white individuals in Nevada.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- 21.4% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in Nevada, not significantly different than the rate of 23.7% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 23.1% among white individuals in Nevada.
- 18.7% of Asian or Pacific Islander individuals with lung cancer in Nevada underwent surgery, significantly lower than the rate of 24.7% among Asian or Pacific Islander individuals nationally, and significantly higher than the rate of 14.2% among white individuals in Nevada.
- 35.1% of Asian or Pacific Islander individuals with lung cancer in Nevada did not receive any treatment, significantly higher than the rate of 19.8% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 36.5% among white individuals in Nevada.
Indigenous Peoples:
- The rate of new lung cancer cases is 21.4 per 100,000 population among Indigenous peoples (American Indians/Alaska Natives) in Nevada, significantly lower than the rate of 39.8 among Indigenous Peoples nationally, and significantly lower than the rate of 48.6 among white individuals in Nevada.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- 40.4% of Indigenous peoples (American Indians/Alaska Natives) with lung cancer in Nevada did not receive any treatment, significantly higher than the rate of 25.0% among Indigenous peoples (American Indians/Alaska Natives) nationally, and not significantly different than the rate of
- 36.5% among white individuals in Nevada.
Other lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Nevada due to too few cases over the time period to allow for accurate analysis.
Summary
The early diagnosis rate in Nevada falls into the bottom tier. The state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Nevada has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
It is alarming that Nevada falls into the bottom tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: October 29, 2025
